Doxorubicin hydrochloride Injection 20 mg in 10 mL (4)

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

doxorubicin hydrochloride, Quantity: 2 mg/mL

Disponible depuis:

Pfizer (Perth) Pty Ltd

forme pharmaceutique:

Injection, solution

Composition:

Excipient Ingredients: sodium chloride; hydrochloric acid; water for injections

Mode d'administration:

Intravenous

Unités en paquet:

1 x 10 mL

Type d'ordonnance:

(S1) This Schedule is intentionally blank

indications thérapeutiques:

Doxorubicin HCl is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer. acute lymphoblastic leukemia acute myeloblastic leukemia Hodgkin lymphoma non-Hodgkin lymphoma metastatic breast cancer metastatic Wilms? tumor metastatic neuroblastomas metastatic soft tissue sarcoma metastatic bone sarcoma metastatic ovarian carcinoma metastatic transitional cell bladder carcinoma metastatic thyroid carcinoma metastatic gastric carcinoma metastatic bronchogenic carcinoma

Descriptif du produit:

Visual Identification: Clear and clean red solution, practically free from visible particles.; Container Type: Vial; Container Material: PP; Container Life Time: 24 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Statut de autorisation:

Listed (Export Only)

Date de l'autorisation:

2019-05-01